Contact Us

Home

About us

Services

AI Excellence

case studies

publications

HEOR Certificationheor Certification

AI for Medical Writing

Contact

  • Turning Insight into Adoption: Essentials of Effective Product Launches

    Turning Insight into Adoption: Essentials of Effective Product Launches

    A successful pharmaceutical product launch is a closely managed process that transforms clinical evidence into real‑world approval across regulators, payers, prescribers, and patients, rather than a one‑off promotional campaign.(1) It begins early in product development with a clear understanding of the treatment pathway and unmet needs, so the product’s value proposition precisely clarifies which patients benefit most, how outcomes improve against standard of care, and why is that significant clinically and economically.(1-3)

    ​Cross‑functional preparation of medical, regulatory, commercial, market access, and manufacturing teams helps align labelling, evidence, pricing assumptions, and supply with the time of approval. This collective planning towards the shared purpose of product launch ensures consistency of the claims made to clinicians and payers with the data and the final outcome, thus minimizing any sudden surprises about safety information, reimbursement, or stock availability.(1, 2, 4)

    ​After this, market access and pricing strategy evaluate whether a clinically strong product can actually reach patients at scale.(5) Value dossiers and health‑economic models must convert trial endpoints into payer‑relevant outcomes, including lower hospitalisations, reduced complication rates, or long‑term cost offsets, for reimbursement decisions and formulary inclusion to support prescriber goals. Careful use of patient access programs or outcomes‑based agreements can also alleviate payer concerns in high‑cost or high‑uncertainty groups.(6)

    ​Stakeholder‑specific communication helps connect data with everyday clinical decisions. For prescribers, scientific communication through peer‑reviewed publications, congress presentations, and medical education clarifies positioning, dosing, safety, and how the product aligns with the guidelines. For patients and caregivers, precise, compliant materials help explain benefits, risks, and adherence expectations in relevant language, facilitated by helplines or digital tools where appropriate.(7)

    Several pharmaceutical launches have shown how incorporating evidence, access, and stakeholder engagement have immensely changed outcomes. For instance, evaluations of successful specialty drug launches emphasize early engagement of market access teams as it facilitates the alignment of clinical development with payer needs. This has reportedly built strong contracts and affordability programs for faster uptake and fewer access barriers, even at comparatively high prices. However, post‑marketing surveillance studies have shown inadequate planning for real‑world safety data to result in product re-labelling or withdrawals, highlighting the need of integrating continuous evidence generation and pharmacovigilance into the core launch strategy early on.(4, 7, 8, 9)

    ​In conclusion, an efficient product launch must treat the first months in the market as a continuous learning process. Real‑world evidence from post-marketing studies, registries, and prescription patterns must be reincorporated into updated guidance, enhanced messaging, and access negotiations, while safety and efficacy data in routine practice helps adjust the initial positioning.(1) Organizations that imbibe this learning‑oriented, patient‑centred approach into every launch achieve a continuous capacity to improve both commercial performance and health impact over time.

    Become A Certified HEOR Professional – Enrol yourself here!

    References

    1. Naidoo P, Bouharati C, Rambiritch V, Jose N, Karamchand S, Chilton R, Leisegang R. Real-world evidence and product development: Opportunities, challenges and risk mitigation. Wien Klin Wochenschr. 2021 Aug;133(15-16):840-846.
    2. Strongin RJ. Pharmaceutical Marketplace Dynamics [Internet]. Washington (DC): National Health Policy Forum; 2000 May 31. (Issue Brief, No. 755.) [Accessed online on 22nd December 2025] Available from: https://www.ncbi.nlm.nih.gov/books/NBK559751/
    3. Årdal C, Lopert R, Mestre-Ferrandiz J. Overview of the Market for Novel Medicines in the WHO European Region [Internet]. Copenhagen Ø, Denmark: World Health Organization; 2022. 3 The pharmaceutical sector: an evolving market. [Accessed online on 22nd December 2025] Available from: https://www.ncbi.nlm.nih.gov/books/NBK587857/
    4. Alexander S. 2021. New Product Launch Success: A Literature Review. Acta Universitatis Agriculturae et Silviculturae Mendelianae Brunensis. 2021; 69(1):151-176.
    5. Ntais C, Talias MA, Fanourgiakis J, Kontodimopoulos N. Managing Pharmaceutical Costs in Health Systems: A Review of Affordability, Accessibility and Sustainability Strategies. J Mark Access Health Policy. 2024 Dec 10;12(4):403-414.
    6. Goodman C, Karnes E, Faulkner E, et al. Cost-effectiveness Considerations in the Approval and Adoption of New Health Technologies. Department of Health and Human Services Assistant Secretary for Planning and Evaluation. 2007. [Accessed online on 22nd December 2025] Available from: https://aspe.hhs.gov/sites/default/files/private/pdf/75096/report.pdf
    7. Gonella S, Di Giulio P, Brofferio L, Riva-Rovedda F, Cotogni P, Dimonte V. Stakeholders’ Perspective on the Key Features of Printed Educational Resources to Improve the Quality of Clinical Communication. Healthcare (Basel). 2024 Feb 4;12(3):398.
    8. Büssgen M, Stargardt T. Changes in launch delay and availability of pharmaceuticals in 30 European markets over the past two decades. BMC Health Serv Res. 2022 Nov 30;22(1):1457.
    9. Verma DD. A comprehensive review of phase IV trials and post-marketing surveillance. International Journal of Pharmacology and Clinical Research 2025; 7(2):207-214.

    MarksMan Healthcare

    , ,

  • Adaptive Licensing and Real World Evidence (RWE)

    Adaptive Licensing and Real World Evidence (RWE)

    We all want safe and effective medicines to reach patients as soon as possible, but as we know, drug development, market authorization and payer assessment are all slow sections of a long and drawn out journey for a drug. But what if patients could have access to medicines not just months earlier, but potentially 8 years earlier? This is exactly what the European Medicines Agency (EMA) have in mind, as they lead a broad and diverse group of key stakeholders towards a root-and-branch upheaval of current practice. Adaptive Licensing (AL) (earlier known as adaptive pathways; AP), an ambitious and evolving new initiative which incorporates Real World Evidence (RWE): clinical data collected outside of a conventional randomized controlled trial. AL reforms the existing regulatory approach.

    In March 2014 EMA launched a pilot project to explore the adaptive pathways approach, a scientific concept of medicines development and data generation intended for medicines that address patients’ unmet medical needs. AL seeks to balance timely access for patients who are likely to benefit most from the medicine with the need to provide adequate evolving information on the benefits and risks of the medicine itself. AL is not a new route of approval for medicines. It makes use of existing approval tools, in particular conditional marketing authorization, which has been in operation in the European Union (EU) since 2006. It also builds on the experience gained with strengthened post-marketing monitoring tools introduced by the 2012 pharmacovigilance legislation (e.g., post-authorization studies and patient registries). The adaptive pathways concept is not meant to be applicable to all medicines, but only to medicines that are likely to offer help for a patient population with an unmet medical need, and where the criteria for adaptive pathways apply.

    Notwithstanding the classic randomized controlled clinical trials (RCTs) are Gold Standard for the regulatory approval of new technologies, their inherent generation of efficacy and safety data, are not always utilizable in the daily context. Items such as ‘homogenous populations without other diseases than the one explored in the study’, ‘placebo comparator, not the standard treatment or other active comparator’, and ‘high adherence,’ are just to nominate some points, which are far from the regular use of a medication on the part of patients and healthcare professionals. Even though currently, in parallel with clinical studies, collection programs of observational information are more and more generated, the available evidence is limited and onerous in case of necessity of large volumes; at least by means of clinical studies. This can be overcome with the help of real-world data.

    RWE refers to the planned and systematic recollection of the data generated outside the clinical studies. Adaptive approaches link decision making to an evolving evidence base, parts of which are frequently seen as being derived from analyses of observational data gathered from sources such as electronic medical records, registries or administrative databases. Acceptance of such evidence is an important issue- regulatory authorities and payers are currently prepared to accept observational data to support manufacturers’ efficacy/effectiveness claims only in limited circumstances. In the pilot project, the concept of RWE was expressly intended as wide ranging, encompassing different types of observational research that may be utilized to supplement randomized clinical trials. This was to encourage the submission of different approaches, not all of which could be foreseen at the conceptual stage, with the intent to highlight possibilities, needs and maximize the learning potential.

    RWE data collection within AL has the potential to improve our understanding of disease processes, epidemiological factors, and difficult issues such as adherence, which will in turn allow RCTs to become more efficient. Additionally, for many subpopulations, the life span approach to licensing and coverage and learning from real-world experience as advocated by adaptive pathways will become the only viable access route to new treatments in future. Additionally, in-depth knowledge of the natural history of diseases, existing baseline data, as well as other epidemiology aspects gleaned from existing databases or emerging large data networks and reanalysis of past trials helps to make RCTs more efficient and identify surrogate endpoints, and may increasingly obviate the need for concurrent control groups, e.g., in rare diseases. This knowledge and data can also be leveraged for the post-initial licensing evidence generation foreseen under AL, by providing a reference point against which the real-world performance of a treatment can be assessed.

    Further important steps towards enabling AL are currently being taken. Regulators have just begun to explicitly address and communicate “uncertainty” in their templates for benefit–risk assessment. A growing number of regulators and payer (or HTA) organizations involve patients in their decision-making processes. This can be considered as a pertinent analogy for the history of bringing new drugs to market.

    Become a Certified HEOR Professional – Enrol yourself here!

    MarksMan Healthcare

    , , ,
    ,